scholarly journals Functional deficiency in endogenous interleukin‐1 receptor antagonist in patients with febrile infection‐related epilepsy syndrome

2019 ◽  
Vol 85 (4) ◽  
pp. 526-537 ◽  
Author(s):  
Benjamin D. S. Clarkson ◽  
Reghann G. LaFrance‐Corey ◽  
Robert J. Kahoud ◽  
Raquel Farias‐Moeller ◽  
Eric T. Payne ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Interleukin 1 ◽  
Epilepsy Syndrome ◽  
Interleukin 1 Receptor Antagonist ◽  
Functional Deficiency

scholarly journals Towards a Treatment for Neuroinflammation in Epilepsy: Interleukin-1 Receptor Antagonist, Anakinra, as a Potential Treatment in Intractable Epilepsy

2021 ◽  
Vol 22 (12) ◽  
pp. 6282
Author(s):  
Gaku Yamanaka ◽  
Yu Ishida ◽  
Kanako Kanou ◽  
Shinji Suzuki ◽  
Yusuke Watanabe ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Small Sample Size ◽  
Interleukin 1 ◽  
Intractable Epilepsy ◽  
Evidence Base ◽  
Small Sample ◽  
Epilepsy Syndrome ◽  
Interleukin 1 Receptor Antagonist ◽  
Epileptic Syndromes ◽  
Systemic Symptoms

Febrile Infection-Related Epilepsy Syndrome (FIRES) is a unique catastrophic epilepsy syndrome, and the development of drug-resistant epilepsy (DRE) is inevitable. Recently, anakinra, an interleukin-1 receptor antagonist (IL-1RA), has been increasingly used to treat DRE due to its potent anticonvulsant activity. We here summarized its effects in 38 patients (32 patients with FIRES and six with DRE). Of the 22 patients with FIRES, 16 (73%) had at least short-term seizure control 1 week after starting anakinra, while the remaining six suspected anakinra-refractory cases were male and had poor prognoses. Due to the small sample size, an explanation for anakinra refractoriness was not evident. In all DRE patients, seizures disappeared or improved, and cognitive function improved in five of the six patients following treatment. Patients showed no serious side effects, although drug reactions with eosinophilia and systemic symptoms, cytopenia, and infections were observed. Thus, anakinra has led to a marked improvement in some cases, and functional deficiency of IL-1RA was indicated, supporting a direct mechanism for its therapeutic effect. This review first discusses the effectiveness of anakinra for intractable epileptic syndromes. Anakinra could become a new tool for intractable epilepsy treatment. However, it does not currently have a solid evidence base.

scholarly journals P0001 / #308: FEBRILE INFECTION-RELATED EPILEPSY SYNDROME (FIRES) TREATED WITH HUMAN RECOMBINAT INTERLEUKIN 1 RECEPTOR ANTAGONIST-ANAKINRA

2021 ◽  
Vol 22 (Supplement 1 3S) ◽  
pp. 38-38
Author(s):  
R. Bustos B ◽  
C. Zapata ◽  
A. Gallardo ◽  
M. Mardones ◽  
M. Fuentes ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Interleukin 1 ◽  
Epilepsy Syndrome ◽  
Interleukin 1 Receptor Antagonist

Mesenchymal Stem Cell-Derived Interleukin 1 Receptor Antagonist Promotes Macrophage Polarization and Inhibits B Cell Differentiation

Stem Cells ◽  
2015 ◽  
Vol 34 (2) ◽  
pp. 483-492 ◽  
Author(s):  
Patricia Luz-Crawford ◽  
Farida Djouad ◽  
Karine Toupet ◽  
Claire Bony ◽  
Marcella Franquesa ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cell Differentiation ◽  
Mesenchymal Stem Cell ◽  
B Cell ◽  
Receptor Antagonist ◽  
Macrophage Polarization ◽  
Interleukin 1 ◽  
B Cell Differentiation ◽  
Interleukin 1 Receptor Antagonist
Sign in / Sign up

Export Citation Format

Share Document